How effective is mavacamten?

Mavacamten (mavacamten) is a drug that has attracted widespread attention in the field of heart diseases, especially in the treatment of obstructive hypertrophic cardiomyopathy (HCM). As the first cardiac myosin inhibitor approved by the U.S. Food and Drug Administration (FDA), Mavacartide provides eligible adult patients with a new treatment option that can significantly improve their function and symptoms.

Research shows that Mavakate can effectively reduce the excessive contraction of the heart by selectively regulating the conformation of cardiac myosin and reducing the probability of cross-bridge formation during myocardial systole and diastole. This mechanism is crucial for alleviating left ventricular outflow tract obstruction (LVOT obstruction) caused by myocardial thickening in patients with HCM. Specifically, Mavacate shifts myosin populations into a more energy-efficient state, which helps increase the heart's filling capacity and improves heart function.

Mavacatel’s effectiveness has been proven in two major clinical studies. These studies compared Mavacartide with placebo to assess its effect on patients' exercise capacity and symptom improvement. In the first study, which included 251 patients, 37% of patients in the Mavacartide group achieved a predetermined level of improvement after 30 weeks of treatment, while only 17% in the placebo group achieved the same effect. This result shows that Mavaceta has significant advantages in improving patients' quality of life and exercise ability.

The second study looked at 112 patients who were eligible for interval reduction therapy (SRT). After 16 weeks of treatment with Mavacartide, 18% of patients were able to continue SRT or remain eligible, compared with 77% of patients in the placebo group. This data reflects the potential of mavacate to help patients maintain treatment options, further underscoring its importance in the management of HCM.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos